Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
06/2012
06/21/2012US20120156206 C-met antibody combinations
06/21/2012US20120156205 Monoclonal antibodies to progastrin
06/21/2012US20120156200 Method of treating cancer
06/21/2012US20120156199 Use of picoplatin to treat colorectal cancer
06/21/2012US20120156198 Antibodies against IL-18R1 and uses thereof
06/21/2012US20120156197 Combination therapy with mdm2 and efgr inhibitors
06/21/2012US20120156191 Anti-jam-a antibodies
06/21/2012US20120156175 Composition for inducing migration of neural stem cells containing periostin as effective ingredient
06/21/2012US20120156170 Drug composition for angiogenesis therapy
06/21/2012US20120156169 Recombinant mycobacterium strain expressing a mycobacterial fap protein under the control of a promoter active under hypoxia and its application for cancer therapy
06/21/2012US20120156168 Viruses for the treatment of cellular proliferative disorders
06/21/2012US20120156164 In situ-forming hydrogel for tissue adhesives and biomedical use thereof
06/21/2012US20120156144 Foamable Compositions, Kits and Methods for Hyperhidrosis
06/21/2012US20120156141 Nanoparticle composition and associated methods thereof
06/21/2012US20120156138 Methods and Compositions for the Treatment of Medical Conditions Involving Cellular Reprogramming
06/21/2012US20120156133 Non-radioactive phospholipid compounds, compositions, and methods of use
06/21/2012US20120156131 Diagnosis and treatment of tumors
06/21/2012US20120156129 Novel antibodies
06/21/2012US20120156128 Controllable release composition and method for preparing same
06/21/2012CA2821984A1 Thiosemicarbazone compounds and use in the treatment of cancer
06/21/2012CA2821975A1 Novel n-(4-(azetidine - 1 - carbonyl)phenyl)-(hetero-) arylsulfonamide derivatives as pyruvate kinase m2 (pmk2) modulators
06/21/2012CA2821837A1 2-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
06/21/2012CA2821834A1 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
06/21/2012CA2821829A1 Imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
06/21/2012CA2821827A1 6-thio-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
06/21/2012CA2821819A1 6-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
06/21/2012CA2821817A1 Substituted 6-imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
06/21/2012CA2821811A1 Treatment of spinal cord injury and traumatic brain injury using amnion derived adherent cells
06/21/2012CA2821777A1 Substituted pyrimido[1,2-b]indazoles and their use as modulators of the pi3k/akt pathway
06/21/2012CA2821712A1 Substituted n-(1h-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type iii receptor tyrosine kinase inhibitors
06/21/2012CA2821102A1 Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine
06/21/2012CA2821080A1 Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer
06/21/2012CA2820871A1 Disease inhibiting agent
06/21/2012CA2820078A1 Tricyclic pi3k inhibitor compounds and methods of use
06/21/2012CA2819620A1 Modulators of histone methyltransferase, and methods of use thereof
06/21/2012CA2819515A1 Cyp11b, cyp17, and/or cyp21 inhibitors
06/21/2012CA2819436A1 Combination therapy of an afucosylated cd20 antibody with a mdm2 inhibitor
06/21/2012CA2819426A1 Combination therapy comprising vemurafenib and an interferon for use in the treatment of cancer
06/21/2012CA2812223A1 Substituted pyrazolo-quinazoline derivatives as kinase inhibitors
06/20/2012EP2465935A2 Recombinant human interferon-like proteins
06/20/2012EP2465867A2 Peptide vaccines for cancers expressing tumor-associated antigens
06/20/2012EP2465866A2 Peptide vaccines for cancers expressing tumor-associated antigens
06/20/2012EP2465865A2 Peptide vaccines for cancers expressing tumor-associated antigens
06/20/2012EP2465864A2 Peptide vaccines for cancers expressing tumor-associated antigens
06/20/2012EP2465857A1 Methods for synthesizing heterocyclic compounds
06/20/2012EP2465538A2 Use of immunesuppressant receptor
06/20/2012EP2465535A1 Methods for treating conditions associated with MASP-2 dependent complement activation
06/20/2012EP2465520A2 Epitope sequences
06/20/2012EP2465505A1 Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
06/20/2012EP2465501A1 (2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms, and methods of preparation
06/20/2012EP2465494A2 Injectable composition containing hydroxychloroquine for local administration for treating cancer
06/20/2012EP2465491A1 Anti-aging preparation
06/20/2012EP2464730A1 miRNA COMPOUNDS FOR TREATMENT OF PROSTATE CARCINOMA
06/20/2012EP2464666A1 Combination of a human interleukin-6 antagonist and a human interleukin-6 receptor antagonist in therapy of tumour diseases
06/20/2012EP2464663A2 Engineered proteins including mutant fibronectin domains
06/20/2012EP2464656A1 Novel peptide and use thereof
06/20/2012EP2464651A1 New macrolides and their use
06/20/2012EP2464649A1 Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
06/20/2012EP2464647A1 Azaindazoles as btk kinase modulators and use thereof
06/20/2012EP2464642A1 Method of promoting apoptosis and inhibiting metastasis
06/20/2012EP2464640A1 Inhibitors of jnk
06/20/2012EP2464639A1 Pyrimidone derivatives used as tau protein kinase 1 inhibitors
06/20/2012EP2464632A1 Pyrimidone derivatives used as tau protein kinase 1 inhibitors
06/20/2012EP2464423A1 Methods and compositions for treating leukemia
06/20/2012EP2464388A1 Particulate hyaluronic acid formulations for cellular delivery of bioactive agents
06/20/2012EP2464385A2 Photochemical internalization method
06/20/2012EP2464384A2 Photosensitizing compositions
06/20/2012EP2464382A1 Combination therapy of an afucosylated cd20 antibody with bendamustine
06/20/2012EP2464381A1 Anti-angiogenesis therapy for the treatment of previously treated breast cancer
06/20/2012EP2464380A1 Combination therapy of an afucosylated cd20 antibody with fludarabine and/or mitoxantrone
06/20/2012EP2464367A2 Methods of treating cancer using neurotrophin retargeted endopeptidases
06/20/2012EP2464365A2 Methods of treating cancer using tachykinin retargeted endopeptidases
06/20/2012EP2464347A1 Combinations of vascular disrupting agents with inhibitor of apoptosis proteins antagonists
06/20/2012EP2464232A1 Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
06/20/2012EP2464218A2 Treatment of brain metastases with inhibitors of endothelin receptors in combination with a cytotoxic chemotherapy agent
06/20/2012EP2364731A9 Methods of administering anti-TNFalpha antibodies
06/20/2012EP2359855A9 Methods of administering anti-TNFalpha antibodies
06/20/2012EP2227460B1 Therapeutic oxy-phenyl-aryl compounds and their use
06/20/2012EP2203442B1 Substituted pyrrolo-pyrimidine derivatives, process for their preparation and their use as kinase inhibitors
06/20/2012EP2146735B1 Compositions comprising sparc polypeptides
06/20/2012EP2121614B1 Amino nicotinic and isonicotinic acid derivatives as dhodh inhibitors
06/20/2012EP2075258B1 Antibody against rgd in amino acid sequence of extracellular matrix protein and production method and use of the same
06/20/2012EP1877097B1 Aminoacid conjugates of beta-lapachone for tumor targeting
06/20/2012EP1745041B1 Quinoxaline inhibitors of the hedgehog signalling pathway
06/20/2012EP1735348B1 Human anti-epidermal growth factor receptor antibody
06/20/2012EP1546203B1 Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
06/20/2012EP1311267B1 A retroviral immunotherapy
06/20/2012CN1906183B N-acylsulfonamide apoptosis promoters
06/20/2012CN102510865A Nitrogen-containing spiro-ring compound and medicinal use of same
06/20/2012CN102510855A Crystalline forms of n-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quin0lin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide
06/20/2012CN102510854A Alpha-arylmethoxyacrylate derivative, preparation method thereof, and pharmaceutical composition containing same
06/20/2012CN102510759A Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
06/20/2012CN102510719A Treatment of brain metastases with inhibitors of endothelin receptors in combination with a cytotoxic chemotherapy agent
06/20/2012CN102505029A Method for preparing Dinghu pholiota polysaccharide with anti-tumor activity
06/20/2012CN102505006A Modulation of stem and progenitor cell differentiation, assays, and uses thereof
06/20/2012CN102504267A Paclitaxel bonded amphipathic aliphatic polyester-b-polyphosphate high polymer and preparation thereof
06/20/2012CN102504227A Process method for synthesizing lactic acid-lysine copolymer by catalytically opening loop and copolymerizing with acetic bicyclo-guanidine
06/20/2012CN102504039A Extraction process of black corn silk polysaccharide
06/20/2012CN102504026A Full human single chain antibody capable of resisting epidermal growth-factor receptor and application thereof
06/20/2012CN102504025A Estrogen receptors and methods of use
1 ... 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 ... 2211